Q60636
PR
Gene name |
Prdm1 (Blimp1) |
Protein name |
PR domain zinc finger protein 1 |
Names |
B lymphocyte-induced maturation protein 1, Blimp-1, Beta-interferon gene positive regulatory domain I-binding factor, PR domain-containing protein 1 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:12142 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q60636
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q60636-F1 | Predicted | AlphaFoldDB |
34 variants for Q60636
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs238855745 | 4 | A>V | No | EVA | |
| rs3389107319 | 31 | L>P | No | EVA | |
| rs3389093442 | 57 | V>L | No | EVA | |
| rs3389065306 | 71 | D>E | No | EVA | |
| rs3389072405 | 80 | W>R | No | EVA | |
| rs3401088138 | 81 | T>P | No | EVA | |
| rs3389041463 | 86 | E>* | No | EVA | |
| rs3389085873 | 88 | K>N | No | EVA | |
| rs3389041486 | 105 | G>D | No | EVA | |
| rs3389085923 | 113 | S>T | No | EVA | |
| rs3389093433 | 186 | E>D | No | EVA | |
| rs3389100027 | 200 | A>T | No | EVA | |
| rs221364808 | 201 | R>L | No | EVA | |
| rs3400504526 | 202 | E>F | No | EVA | |
| rs3401390097 | 225 | N>I | No | EVA | |
| rs3389097525 | 227 | E>D | No | EVA | |
| rs3389072383 | 241 | H>L | No | EVA | |
| rs3389098719 | 264 | S>N | No | EVA | |
| rs3389077265 | 334 | R>Q | No | EVA | |
| rs3389085838 | 335 | A>T | No | EVA | |
| rs3389108398 | 349 | G>E | No | EVA | |
| rs3400504594 | 360 | P>L | No | EVA | |
| rs3389072418 | 360 | P>S | No | EVA | |
| rs3401268670 | 361 | L>H | No | EVA | |
| rs249204310 | 371 | A>V | No | EVA | |
| rs29352213 | 379 | L>F | No | EVA | |
| rs259435114 | 386 | S>G | No | EVA | |
| rs3389099782 | 391 | T>M | No | EVA | |
| rs222389486 | 520 | L>R | No | EVA | |
| rs3401166015 | 704 | H>Q | No | EVA | |
| rs3400752947 | 706 | K>Q | No | EVA | |
| rs3400504561 | 707 | L>V | No | EVA | |
| rs3399997323 | 740 | N>S | No | EVA | |
| rs3400887707 | 743 | A>S | No | EVA |
No associated diseases with Q60636
7 regional properties for Q60636
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | SET domain | 115 - 239 | IPR001214 |
| domain | Zinc finger C2H2-type | 606 - 633 | IPR013087-1 |
| domain | Zinc finger C2H2-type | 634 - 661 | IPR013087-2 |
| domain | Zinc finger C2H2-type | 662 - 689 | IPR013087-3 |
| domain | Zinc finger C2H2-type | 690 - 717 | IPR013087-4 |
| domain | Zinc finger C2H2-type | 718 - 738 | IPR013087-5 |
| domain | PRDM1, PR/SET domain | 112 - 240 | IPR044413 |
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
8 GO annotations of molecular function
| Name | Definition |
|---|---|
| DNA-binding transcription factor activity | A transcription regulator activity that modulates transcription of gene sets via selective and non-covalent binding to a specific double-stranded genomic DNA sequence (sometimes referred to as a motif) within a cis-regulatory region. Regulatory regions include promoters (proximal and distal) and enhancers. Genes are transcriptional units, and include bacterial operons. |
| DNA-binding transcription repressor activity, RNA polymerase II-specific | A DNA-binding transcription factor activity that represses or decreases the transcription of specific gene sets transcribed by RNA polymerase II. |
| histone deacetylase binding | Binding to histone deacetylase. |
| metal ion binding | Binding to a metal ion. |
| methyltransferase activity | Catalysis of the transfer of a methyl group to an acceptor molecule. |
| promoter-specific chromatin binding | Binding to a section of chromatin that is associated with gene promoter sequences of DNA. |
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase II. |
| sequence-specific double-stranded DNA binding | Binding to double-stranded DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA, e.g. promotor binding or rDNA binding. |
32 GO annotations of biological process
| Name | Definition |
|---|---|
| adaptive immune response | An immune response mediated by cells expressing specific receptors for antigen produced through a somatic diversification process, and allowing for an enhanced secondary response to subsequent exposures to the same antigen (immunological memory). |
| aorta development | The progression of the aorta over time, from its initial formation to the mature structure. An aorta is an artery that carries blood from the heart to other parts of the body. |
| artery morphogenesis | The process in which the anatomical structures of arterial blood vessels are generated and organized. Arteries are blood vessels that transport blood from the heart to the body and its organs. |
| cardiac septum development | The progression of a cardiac septum over time, from its initial formation to the mature structure. |
| cell fate commitment | The commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells. Positional information is established through protein signals that emanate from a localized source within a cell (the initial one-cell zygote) or within a developmental field. |
| coronary vasculature development | The process whose specific outcome is the progression of the blood vessels of the heart over time, from its formation to the mature structure. |
| embryonic placenta development | The embryonically driven process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin. |
| eye photoreceptor cell development | Development of a photoreceptor, a sensory cell in the eye that reacts to the presence of light. They usually contain a pigment that undergoes a chemical change when light is absorbed, thus stimulating a nerve. |
| gene expression | The process in which a gene's sequence is converted into a mature gene product (protein or RNA). This includes the production of an RNA transcript and its processing, translation and maturation for protein-coding genes. |
| germ cell development | The process whose specific outcome is the progression of an immature germ cell over time, from its formation to the mature structure (gamete). A germ cell is any reproductive cell in a multicellular organism. |
| heart valve development | The progression of a heart valve over time, from its formation to the mature structure. A heart valve is a structure that restricts the flow of blood to different regions of the heart and forms from an endocardial cushion. |
| histone arginine methylation | The modification of a histone by addition of a methyl group to an arginine residue. |
| in utero embryonic development | The process whose specific outcome is the progression of the embryo in the uterus over time, from formation of the zygote in the oviduct, to birth. An example of this process is found in Mus musculus. |
| innate immune response | Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens. |
| intestinal epithelial cell development | The process whose specific outcome is the progression of a columnar/cuboidal epithelial cell of the intestine over time, from its formation to the mature structure. |
| kidney development | The process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and/or excretes the end products of body metabolism in the form of urine. |
| maternal placenta development | Maternally driven process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin. |
| morphogenesis of a branching structure | The process in which the anatomical structures of branches are generated and organized. A branch is a division or offshoot from a main stem. Examples in animals would include blood vessels, nerves, lymphatics and other endothelial or epithelial tubes. |
| negative regulation of gene expression | Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). |
| negative regulation of transcription by RNA polymerase II | Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| positive regulation of gene expression | Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). |
| post-embryonic development | The process whose specific outcome is the progression of the organism over time, from the completion of embryonic development to the mature structure. See embryonic development. |
| regulation of cell population proliferation | Any process that modulates the frequency, rate or extent of cell proliferation. |
| regulation of extrathymic T cell differentiation | Any process that modulates the frequency, rate or extent of extrathymic T cell differentiation. |
| regulation of gene expression | Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). |
| regulation of natural killer cell differentiation | Any process that modulates the frequency, rate or extent of natural killer cell differentiation. |
| regulation of NK T cell differentiation | Any process that modulates the frequency, rate or extent of natural killer T cell differentiation. |
| regulation of transcription by RNA polymerase II | Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| response to radiation | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electromagnetic radiation stimulus. Electromagnetic radiation is a propagating wave in space with electric and magnetic components. These components oscillate at right angles to each other and to the direction of propagation. |
| sebum secreting cell proliferation | The multiplication or reproduction of sebocytes by cell division, resulting in the expansion of their population. A sebocyte is an epithelial cell that makes up the sebaceous glands, and secrete sebum. |
| trophoblast giant cell differentiation | The process in which a relatively unspecialized cell acquires specialized features of a trophoblast giant cell of the placenta. Trophoblast giant cells are the cell of the placenta that line the maternal decidua. |
| ventricular septum development | The progression of the ventricular septum over time from its formation to the mature structure. |
4 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q9NQX1 | PRDM5 | PR domain zinc finger protein 5 | Homo sapiens (Human) | PR |
| Q9NQX0 | PRDM6 | Putative histone-lysine N-methyltransferase PRDM6 | Homo sapiens (Human) | PR |
| Q9CXE0 | Prdm5 | PR domain zinc finger protein 5 | Mus musculus (Mouse) | PR |
| A2AGX3 | Prdm11 | PR domain-containing protein 11 | Mus musculus (Mouse) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MREAYLRCWI | FSWKNVWVRP | CQRLHFKTVL | LQGSLLYTAL | DSYSTVQAAP | KSSSGSVKFQ |
| 70 | 80 | 90 | 100 | 110 | 120 |
| GLAETGIMKM | DMEDADMTLW | TEAEFEEKCT | YIVNDHPWDS | GADGGTSVQA | EASLPRNLLF |
| 130 | 140 | 150 | 160 | 170 | 180 |
| KYAANNSKEV | IGVVSKEYIP | KGTRFGPLIG | EVYTNDTVPK | NANRKYFWRI | YSREEFHHFI |
| 190 | 200 | 210 | 220 | 230 | 240 |
| DGFNEEKSNW | MRYVNPAHSA | REQNLAACQN | GMNIYFYTIK | PIPANQELLV | WYCRDFAERL |
| 250 | 260 | 270 | 280 | 290 | 300 |
| HYPYPGELTV | INLTQTESNP | KQYSSEKNEL | YPKSVPKREY | SVKEILKLDS | NPSKRKDIYR |
| 310 | 320 | 330 | 340 | 350 | 360 |
| SNISPFTLEK | DMDGFRKNGS | PDMPFYPRVV | YPIRAPLPED | FLKASLAYGM | ERPTYITHSP |
| 370 | 380 | 390 | 400 | 410 | 420 |
| LPSSTTPSPP | ASSSPEQSLK | SSSPHSSPGN | TVSPLAPGLP | EHRDSYSYLN | VSYGSEGLGS |
| 430 | 440 | 450 | 460 | 470 | 480 |
| YPGYAPAPHL | PPAFIPSYNA | HYPKFLLPPY | GISSNGLSTM | NNINGINNFS | LFPRLYPVYS |
| 490 | 500 | 510 | 520 | 530 | 540 |
| NLLSGSSLPH | PMLNPASLPS | SLPTDGARRL | LPPEHPKEVL | IPAPHSAFSL | TGAAASMKDE |
| 550 | 560 | 570 | 580 | 590 | 600 |
| SSPPSGSPTA | GTAATSEHVV | QPKATSSVMA | APSTDGAMNL | IKNKRNMTGY | KTLPYPLKKQ |
| 610 | 620 | 630 | 640 | 650 | 660 |
| NGKIKYECNV | CAKTFGQLSN | LKVHLRVHSG | ERPFKCQTCN | KGFTQLAHLQ | KHYLVHTGEK |
| 670 | 680 | 690 | 700 | 710 | 720 |
| PHECQVCHKR | FSSTSNLKTH | LRLHSGEKPY | QCKVCPAKFT | QFVHLKLHKR | LHTRERPHKC |
| 730 | 740 | 750 | 760 | 770 | 780 |
| AQCHKSYIHL | CSLKVHLKGN | CPAGPAAGLP | LEDLTRINEE | IERFDISDNA | DRLEDMEDSV |
| 790 | 800 | 810 | 820 | 830 | 840 |
| DVTSMVEKEI | LAVVRKEKEE | TSLKVSLQRN | MGNGLLSSGC | SLYESSDLSL | MKLPHSNPLP |
| 850 | |||||
| LVPVKVKQET | VEPMDP |